The stock began trading on a post-split basis under the same ticker symbol, SKIN, but with a new CUSIP number: 88331L306. Continental Stock Transfer & Trust Company handled the mechanics. Registered shareholders holding book-entry shares saw their accounts adjusted automatically. Those holding shares through brokers or banks had positions adjusted by their intermediaries. Shareholders holding physical certificates received instructions from Continental for exchange.
No fractional shares were issued. Stockholders who would have received a fractional share got cash in lieu instead.
The company also adjusted the conversion rate on its 7.95% Convertible Senior Secured Notes due 2028 proportionately to reflect the split ratio, per the indenture terms. The administrators of the Company's 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan made equitable changes to all outstanding options, stock appreciation rights, restricted stock units, performance-based restricted stock units, restricted stock and other stock-based awards. These changes also applied to the number of shares available under such plans, applicable plan share limits, and applicable per-share exercise or purchase prices, subject to the terms of the applicable plan, award agreements, offering documents, applicable tax requirements, and rounding conventions.
What this signals
A reverse split at this magnitude signals serious stock price pressure. The company needed to get above $1 per share to avoid delisting. The filing does not disclose the stock price at the time of the announcement, but the need for a 1-for-20 split—the maximum authorized—suggests the stock had fallen well below that threshold.
The company's own forward-looking statements in the press release acknowledge the risks: the split may not sustain a higher per-share price, may reduce trading liquidity, and may not result in regaining Nasdaq compliance. These are not abstract disclaimers. They reflect real uncertainty about whether the structural fix addresses the underlying business problem.
The company also stated that the split "will not change the total number of authorized shares of Class A Common Stock or the par value per share," which remains $0.0001. The split affects all stockholders uniformly and does not alter any stockholder's percentage ownership interest except as a result of how fractional shares were treated.
What owners should track
For medspa operators using HydraFacial equipment or considering it, the reverse split itself changes nothing about the device, the consumables, or the company's service. But it does signal financial stress at the parent company. A delisting would complicate the company's access to capital and could affect product development, support, or pricing over time.
The filing does not disclose current revenue, profitability, cash position, or guidance. It does not explain why the stock fell so far. Operators should monitor quarterly earnings reports and SEC filings for context on the company's financial health and any changes to product strategy or pricing.
The company's product portfolio includes HydraFacial, SkinStylus microneedling, and HydraScalp with Keravive. The filing does not indicate any changes to these offerings or their market positioning.
The company is incorporated in Delaware and maintains its principal executive offices at 3600 E. Burnett Street, Long Beach, California 90815. The filing was made on October 14, 2026, with an accession number of 0001628280-26-065833.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.
